Keunwha teams up with BioDilivery Science

Kunwha Pharmaceutical said on May 27 it has entered into a license and supply agreement with the U.S.-based BioDelivery Sciences International, Inc. for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in Korea. The agreement results in potential milestone payments to BDSI of up to $1,275,000, which includes an upfront payment of $300,000. In add...